Chimeric antigen receptor (CAR) technology involves engineering immune cells, typically T cells, to express synthetic receptors that can recognize specific tumor-associated antigens. These receptors are composed of an antigen-binding domain, a hinge region, a transmembrane domain, and an intracellular signaling domain. Once bound to the target antigen, the CAR activates the T cell to attack and kill the cancer cell. CAR T cell therapy has shown promising results in treating certain types of cancer, particularly hematologic malignancies like leukemia and lymphoma. This innovative approach to immunotherapy has the potential to revolutionize cancer treatment and has sparked a great deal of interest in the field of oncology research.